MICAL redox enzymes and actin remodeling: New links to classical tumorigenic and cancer pathways

Jimok Yoon, Jonathan R. Terman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

MICAL Redox enzymes have recently emerged as direct regulators of cell shape and motility–working through specific reversible post-translational oxidation of actin to disassemble and remodel the cytoskeleton. Links are also now emerging between MICALs and cancer, including our recent results that regulation of MICAL sensitizes cancer cells to the cancer drug Gleevec. Targeting this new actin regulatory enzyme system may thus provide new therapeutic options for cancer treatment.

Original languageEnglish (US)
Article numbere1384881
JournalMolecular and Cellular Oncology
Volume5
Issue number1
DOIs
StatePublished - Jan 2 2018

Fingerprint

Oxidation-Reduction
Actins
Enzymes
Neoplasms
Cell Shape
Cytoskeleton
Pharmaceutical Preparations
Therapeutics

Keywords

  • Abl
  • Attraction
  • Chemotropic
  • Growth Factors
  • Kinase
  • Phosphorylation
  • Plexins
  • Post-translational Modification
  • Repulsion
  • Semaphorins

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine

Cite this

MICAL redox enzymes and actin remodeling : New links to classical tumorigenic and cancer pathways. / Yoon, Jimok; Terman, Jonathan R.

In: Molecular and Cellular Oncology, Vol. 5, No. 1, e1384881, 02.01.2018.

Research output: Contribution to journalArticle

@article{aa028be2f3a1459b90a92619046a4449,
title = "MICAL redox enzymes and actin remodeling: New links to classical tumorigenic and cancer pathways",
abstract = "MICAL Redox enzymes have recently emerged as direct regulators of cell shape and motility–working through specific reversible post-translational oxidation of actin to disassemble and remodel the cytoskeleton. Links are also now emerging between MICALs and cancer, including our recent results that regulation of MICAL sensitizes cancer cells to the cancer drug Gleevec. Targeting this new actin regulatory enzyme system may thus provide new therapeutic options for cancer treatment.",
keywords = "Abl, Attraction, Chemotropic, Growth Factors, Kinase, Phosphorylation, Plexins, Post-translational Modification, Repulsion, Semaphorins",
author = "Jimok Yoon and Terman, {Jonathan R.}",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/23723556.2017.1384881",
language = "English (US)",
volume = "5",
journal = "Molecular and Cellular Oncology",
issn = "2372-3556",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - MICAL redox enzymes and actin remodeling

T2 - New links to classical tumorigenic and cancer pathways

AU - Yoon, Jimok

AU - Terman, Jonathan R.

PY - 2018/1/2

Y1 - 2018/1/2

N2 - MICAL Redox enzymes have recently emerged as direct regulators of cell shape and motility–working through specific reversible post-translational oxidation of actin to disassemble and remodel the cytoskeleton. Links are also now emerging between MICALs and cancer, including our recent results that regulation of MICAL sensitizes cancer cells to the cancer drug Gleevec. Targeting this new actin regulatory enzyme system may thus provide new therapeutic options for cancer treatment.

AB - MICAL Redox enzymes have recently emerged as direct regulators of cell shape and motility–working through specific reversible post-translational oxidation of actin to disassemble and remodel the cytoskeleton. Links are also now emerging between MICALs and cancer, including our recent results that regulation of MICAL sensitizes cancer cells to the cancer drug Gleevec. Targeting this new actin regulatory enzyme system may thus provide new therapeutic options for cancer treatment.

KW - Abl

KW - Attraction

KW - Chemotropic

KW - Growth Factors

KW - Kinase

KW - Phosphorylation

KW - Plexins

KW - Post-translational Modification

KW - Repulsion

KW - Semaphorins

UR - http://www.scopus.com/inward/record.url?scp=85050778153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050778153&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1384881

DO - 10.1080/23723556.2017.1384881

M3 - Article

C2 - 29404387

AN - SCOPUS:85050778153

VL - 5

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

SN - 2372-3556

IS - 1

M1 - e1384881

ER -